Search

Displaying results 4561 - 4570 of 10000 in total
  1. Pathway

    Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:1(13Z))

    smpdb.ca/view/SMP0015888
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine +1 more
  2. Pathway

    Phosphatidylcholine Biosynthesis PC(18:1(9Z)/24:1(15Z))

    smpdb.ca/view/SMP0030234
    Metabolic

    Phosphatidylcholines (PC) are a class of phospholipids that incorporate a phosphocholine headgroup into a diacylglycerol backbone. They are the most abundant phospholipid in eukaryotic cell membranes and has both structural and signallin...

    Drugs: Ademetionine · Choline · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium +2 more
  3. Pathway

    Acylcarnitine (5Z,8Z,13E,15S)-11,12,15-trihydroxyicosa-5,8,13-trienoylcarnitine

    smpdb.ca/view/SMP0124375
    Metabolic

    (5Z,8Z,13E,15S)-11,12,15-trihydroxyicosa-5,8,13-trienoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, (5Z,8Z,13E,15S)-11,12,15-trihydroxyicosa-5,8,13-trienoyl-CoA reacts with L-carnitine to form (5Z,8Z,13E,15S)-11,12,15-trihydroxyicosa-5,8,13-trienoylcarnitine.

    Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 more
  4. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    The primary goal of lifelong treatment of PKU, as recommended by the American College of Medical Genetics and Genomics (ACMG) guidelines, is to maintain blood Phe concentration in the range of 120 µmol … [L42725] It is advantageous over currently available management therapies for PKU, such as [DB00360], that are ineffective to many patients due to long-term adherence issues or inadequate Phe-lowering

  5. Drug

    Chlorphenesin

    go.drugbank.com/drugs/DB00856
    Approved

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  6. Drug

    Filgotinib

    go.drugbank.com/drugs/DB14845
    ApprovedInvestigational

    [A189165] Non-selective JAK inhibitors like [tofacitinib] target JAK1 and JAK3 subtypes with minimal activity at JAK2. In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. … [A189165] 50-70% of patients with RA are unable to achieve sustained clinical remission despite the availability of several treatments including disease-modifying anti-rheumatic drugs (DMARDS) like [methotrexate

  7. Drug

    Pamrevlumab

    go.drugbank.com/drugs/DB14952
    Investigational

    Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).

  8. Drug

    TAK-475

    go.drugbank.com/drugs/DB05317
    Investigational

    TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.

  9. Drug

    Queuine

    go.drugbank.com/drugs/DB14732
    ExperimentalNutraceutical

    Queuine is a derivative of [7-Deazaguanine]. Bacteria possess the exclusive ability to synthesize queuine, which is then salvaged and passed on to plants and animals.

  10. Drug

    2-deoxyglucose

    go.drugbank.com/drugs/DB08831
    Investigational

    As an experimental drug, 2-deoxyglucose was demonstrated to work as an anticonvulsant in temporal lobe epilepsy. … 2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel).

    Synonyms: 2-DG, 2-deoxy-D-glucose